Alpha Tau: First rGBM Patient Treated in Israel Highlights Drive to Advance Brain Cancer Program

Research evidence excerpt

Alpha Tau: First rGBM Patient Treated in Israel Highlights Drive to Advance Brain Cancer Program

Equity Research

U.S. Small & Mid Cap Biotechnology

23 June 2026

Alpha Tau

First rGBM Patient Treated in Israel

Highlights Drive to Advance Brain First Look

DRTS OVERWEIGHTCancer Program

U.S. Small & Mid Cap POSITIVE

Recurrent glioblastoma represents a significant unmet need Biotechnology Price Target USD 17.00

and initial data is promising. Expanded clinical footprint will Price (22-Jun-26) USD 10.03

drive additional interest, in our view. Potential Upside/Downside +69.5% Source: Bloomberg, Barclays Research

DRTS announced via pres release the first patient with recurrent glioblastoma (rGBM) treated

with Alpha DaRT on the ALL clinical protocol in Israel, also marking the first rGBM patient Lukas Shumway, PhD

treated with Alpha DaRT outside of the US. The ALL clinical protocol is a broad-access clinical +1 212 526 7293

trial conducted at Hadassah University Medical Center in Jerusalem, Israel that is open to lukas.shumway@barclays.com

patients with a wide range of solid tumor types to which Alpha DaRT sources can be delivered, BCI, US

who do not qualify for participation in other existing Alpha Tau clinical trials or who have no Etzer Darout, PhD, MBA

remaining standard treatment alternatives according to the treating physician. The +1 212 526 6940

announcement highlights DRTS's commitment to rapidly advancing the Alpha DaRT brain etzer.darout@barclays.com

cancer program. BCI, US

Recall, DRTS recently announced the FDA clearance to complete enrollment in the US REGAIN

feasibility study with the remaining 7 patient slots, without the one-patient-per-month barrier

initially put in place by FDA. The company noted in that press release the increased demand for